Experts agree on surgical standards for unilateral Wilms tumo
Press Release November 3, 2026
Experts agree on surgical standards for unilateral Wilms tumo

KNOXVILLE, TN, November 03, 2026 /24-7PressRelease/ -- A new expert consensus sets out a standardized framework for the surgical management of unilateral Wilms tumor (WT), the most common primary malignant renal tumor in children. It tackles decisions that still vary widely, including upfront surgery versus preoperative chemotherapy, biopsy, nephron-sparing surgery (NSS), lymph node sampling, renal vessel control, tumor thrombus, rupture, recurrence, metastases, minimally invasive surgery (MIS), horseshoe kidney, and special age groups. By outlining surgical principles and individualized pathways, the consensus seeks to reduce tumor rupture, iatrogenic progression, recurrence, and unnecessary organ removal while preserving renal function and improving long-term outcomes. It stresses complete tumor resection, accurate lymph node sampling, multidisciplinary care, and evidence-informed surgical judgment.

WT outcomes have improved substantially through progress in molecular diagnosis, chemotherapy, radiotherapy, and surgery. Yet surgical management remains inconsistent, especially for large tumors, adjacent-organ invasion, intravascular extension, nephron-sparing surgery (NSS), and lymph node biopsy. Surgeons also come from different specialties, which may contribute to variations in practice.. Nonstandard procedures can cause tumor rupture, incomplete staging, recurrence, and iatrogenic progression. Computed tomography (CT) and magnetic resonance imaging (MRI) help identify risk features but have limited sensitivity for rupture. Lymph node size on imaging cannot reliably confirm metastasis. Preoperative imaging also cannot reliably detect every high-risk feature. Given these challenges, further research and consensus are needed to standardize surgical decision-making for unilateral WT.

The consensus was developed by the Oncology Surgery Group and Urology Surgery Group of Pediatric Surgery Branch of the Chinese Medical Association. It was published in World Journal of Pediatric Surgery on 17 June 2026 (DOI: 10.1136/wjps-2026-001204). Based on 17 clinical questions, the authors provide 34 recommendations on surgical timing, biopsy, incision, renal vessel control, lymph node sampling, tumor thrombus, rupture, recurrence, metastases, NSS, minimally invasive surgery (MIS), horseshoe kidney, special populations, and follow-up. The guidance targets pediatric surgeons, oncologists, urologists, and multidisciplinary teams.

The consensus prioritizes complete local resection, accurate lymph node staging, and histological evaluation while minimizing complications. Immediate radical nephrectomy is recommended for resectable tumors; preoperative chemotherapy is advised for selected patients with high-risk or initially unresectable disease. Immediate surgery is discouraged in in certain circumstances, including confirmed germline WT1 (Wilms tumor 1) mutation, solitary kidney, severe anesthetic risk, or tumor thrombus above the hepatic veins. Percutaneous biopsy is generally not recommended, but is suggested when renal origin is unclear, benign or non-WT disease is suspected, or in stage IV patients and those older than 10 years. A transverse abdominal or thoracoabdominal incision is preferred. Renal pedicle vessels should be ligated early when possible. Adequate lymph node sampling, ideally 6 to 10 nodes from renal hilar, aortocaval, paraaortic, aortic bifurcation, celiac truck, superior mesenteric artery and iliac sites, improves staging and keeps the false-negative rate below 10%. The ureter should be divided distal to the iliac bifurcation. Adrenal and adjacent organs should be preserved unless directly invaded. Tumor thrombus management follows Daum classification, with neoadjuvant chemotherapy for thrombi above hepatic veins and multidisciplinary care for atrial extension. For recurrence, second-line chemotherapy is preferred; late isolated pulmonary or central nervous system lesions may be resected. NSS is not routine and requires strict criteria; MIS may be considered in selected cases at experienced centers, with conversion to open surgery when necessary.

The consensus is intended as a practical framework rather than a rigid protocol. They said complete resection and accurate staging remain non-negotiable, yet surgeons must balance oncologic control with renal preservation and avoid unnecessary harm. They emphasized that multidisciplinary discussion is essential for complex thrombus, recurrent disease, and unusual presentations. Conversion from MIS to open surgery, they said, should be viewed as sound judgment rather than failure. The goal is safer surgery, better staging, and fewer avoidable recurrences.

This consensus can help pediatric surgeons, oncologists, urologists, radiologists, and pathologists align care around common standards. Its recommendations support preoperative risk assessment, appropriate chemotherapy, adequate lymph node sampling, organ-preserving approaches when safe, and structured follow-up. In resource-limited settings, the framework may also guide referral and multidisciplinary planning. The authors call for future studies to refine patient selection for NSS and MIS, improve rupture prediction, standardize lymph node mapping, and clarify anticoagulation and radiotherapy decisions. Ultimately, the consensus aims to support more consistent, individualized care for children with unilateral WT.

References
DOI
https://doi.org/10.1136/wjps-2026-001204

Original Source URL
10.1136/wjps-2026-001204

About World Journal of Pediatric Surgery
World Journal of Pediatric Surgery (WJPS), founded in 2018, is the open-access, peer-reviewed journal in the field of pediatric surgery. It is sponsored by Zhejiang University and Children's Hospital, Zhejiang University School of Medicine, and published by BMJ Group. WJPS aims to be a leading international platform for advances in pediatric surgical research and practice. Indexed in PubMed, ESCI, Scopus, CAS, DOAJ, and CSCD, WJPS achieved an Impact Factor (IF) of 2.2/Q2 and a CiteScore of 2.5.

Chuanlink Innovations, where revolutionary ideas meet their true potential. Our name, rooted in the essence of transmission and connection, reflects our commitment to fostering innovation and facilitating the journey of ideas from inception to realization.

Related Link:
http://chuanlink-innovations.com

# # #

Contact Information

Khôi Hải

KANTOR IMIGRASI KELAS I KHUSUS NON TPI JAKARTA BARAT

JAKARTA, BARAT

INDONESIA

Telephone: 13320697968

Email: Email Us Here

Website: Visit Our Website